Immunomedics, Inc. (IMMU)
|Net Income (ttm)||-353.41M|
|Trading Day||Oct 23, 2020|
|Day's Range||87.59 - 87.93|
|52-Week Range||8.80 - 87.93|
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to ge...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (Nasdaq: IMMU) f...
LEIDEN, Netherlands, Oct. 20, 2020 /PRNewswire/ -- ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its prem...
Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug con...
These are the stocks with the best value, fastest growth, and most momentum for October 2020.
Some investors are questioning whether the $21 billion Gilead Sciences Inc. (NASDAQ:GILD) agreed to pay for Immunomedics Inc. (NASDAQ:IMMU) last week was too much.
These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.
As of late, it has definitely been a great time to be an investor Immunomedics.
Results from a study of Trodelvy presented over the weekend suggest Gilead Sciences' $21 billion buyout offer was a smart move.
Immunomedics (IMMU) releases data from different cancer studies on its lead drug, Trodelvy.
SAN DIEGO, Sept. 20, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immunomedics Inc. (NASDAQ: IMMU) ("Imm...
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
Trodelvy significantly red uced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemothera py
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Immunomedics, Inc. - IMMU
NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in N...
Find out what's behind their big run-ups to see if they can make it happen again.
Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) Results include partial responses in small cohor...
It’s an exciting time for mergers and acquisitions in some of the hottest sectors -- including software, cloud services, artificial intelligence and health care. Here are four major mergers to...
After tumbling to the lowest level in more than a decade in the second quarter, global M&A activity gathered steam in September following the flurry of latest deal activities.
Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.
Gilead Sciences Inc. (GILD) Gilead Sciences to Acquire Immunomedics Conference Call (Transcript)
Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market Bubbles
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
It's going to be a while before we know if Gilead's $21 billion deal will pay off.
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Immunomedics, Inc.
IMMUNOMEDICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Immunomedics - IMMU
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Immunomedics (IMMU) is seeing IMMU stock soar higher Monday following news that it will be acquired by Gilead (GILD) for $21 billion. The post Immunomedics News: IMMU Stock Skyrockets 99% on G...
Gilead Sciences And Immunomedics: Buy Post-Market Reaction
Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc.
Shares of Gilead Sciences Inc rose 3.2% on Monday, reversing their premarket losses as investors shrugged off concerns over the steep premium the U.S. drugmaker was willing to pay for Immunome...
M&A Activities Intensify in Pharma Industry.
Gilead Sciences drew mixed reactions from analysts after the company announced its largest acquisition ever, gaining a possible flagship cancer treatment. GILD stock rose on the news.
Merck, Gilead and Lilly make progress on an otherwise slow news day.
Immunomedics Inc. (NASDAQ: IMMU) shares more than doubled on Monday after the firm announced that it would be acquired by Gilead Sciences Inc.
Gilead Sciences to acquire Immunomedics in $21 billion deal
Immunomedics Executive Chairman Dr.
Gilead (GILD) looks to fortify its oncology portfolio with the acquisition of Immunomedics and the addition of Trodelvy to its portfolio.
Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.
Immunomedics ties the knot with Gilead Sciences in a $21 billion merger agreement.
Gilead Sciences Inc (NASDAQ: GILD) said late on Sunday that it will buy Immunomedics (biotech company) for £16.32 billion. The acquisition will help Gilead expand its footprint in oncology as ...
Gilead CEO Daniel O'Day on acquisition of cancer drugmaker Immunomedics
Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead's availability of cancer treatments, the companies announced on Sunday.
Gilead to buy Immunomedics, expanding cancer drug portfolio
Gilead is buying biotech company Immunomedics for $21 billion dollars.
After initial reports emerged on Saturday about a potential acquisition deal, Gilead Sciences Inc (NASDAQ: GILD) confirmed that it's set to purchase Immunomedics Inc (NASDAQ: IMMU).
The big purchase adds one of the year's most highly anticipated new cancer therapies to Gilead's product line.
Immunomedics Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Immunomedics, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – IMMU
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Immunomedics, Inc. (NASDAQ: IMMU) to Gilead Sciences, Inc.
Gilead Sciences will acquire biopharmaceutical company Immunomedics for $21 billion, the company announced on Sunday. The acquisition will expand Gilead's portfolio of treatments for various t...
Gilead Sciences will acquire biopharmaceutical company Immunomedics Inc. for $21 billion, a deal that will expand Gilead’s availability of cancer treatments, the company announced on Sunday.
Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on S...
Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomed...
Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc.
Initial partnership discussions between Gilead Sciences Inc and biopharmaceutical company Immunomedics Inc have shifted to acquisition, which would mean an expansion of Gilead’s portfolio of c...
Immunomedics, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Color... [Read more...]
|Stock Exchange |
|Ticker Symbol |